Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics

Author(s): Matilde Y. Follo, Sara Mongiorgi, Carlo Finelli, Manuela Piazzi, Irene Faenza, Giulia Ramazzotti, Patrizia Santi, James A. McCubrey, Alberto M. Martelli, Lucio Cocco.

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 13 , 2012

Submit Manuscript
Submit Proposal

Abstract:

Among cellular second messengers inositides play key roles in signal transduction pathways. Indeed, nuclear phosphoinositide- specific phospholipase C (PI-PLC) β1 and Akt are involved in cell cycle progression and apoptosis. Nuclear lipid metabolism has raised interest in the last years, mainly because of its link with haematopoietic progenitor cells. Myelodysplastic syndromes (MDS) are stem-cell clonal diseases characterized by an impaired hempoiesis and a differentiation defect in one or more of the bone marrow lineages, often leading to progression to acute myeloid leukaemia (AML). The MDS evolution to AML is not completely understood but, at a molecular level, the nuclear inositide signalling pathways can play an important role in this process.

Keywords: Signal transduction, epigenetics, PI-PLCβ1, myelodysplastic syndromes, nucleus, apoptosis, hempoiesis, phospholipase, immunosuppressive, cytogenetic

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 13
Year: 2012
Page: [1751 - 1754]
Pages: 4
DOI: 10.2174/138161212799859710
Price: $58

Article Metrics

PDF: 7